ConcertAI, the leading oncology real-world evidence data and AI SaaS technology company, has announced a strategic collaboration with NVIDIA. This partnership aims to advance a comprehensive set of translational and clinical development solutions within the ConcertAI CARA AI platform, leveraging NVIDIA’s cutting-edge AI and accelerated computing technologies.
Subtopics:
Collaboration Overview:
- ConcertAI and NVIDIA collaborate to enhance the CARA AI platform.
- Utilizes NVIDIA Inference microservices (NIM), including Llama 3 NIM, CUDA-X microservices, and the NeMo platform.
Comprehensive Oncology Data Repository:
- ConcertAI has assembled the largest multi-modal oncology data repository, representing over 8 million patients.
- Partnership with ASCO CancerLinQ program and molecular diagnostic partners expands data capabilities.
- Data set includes genomic, transcriptomic, digital pathology, radiology, clinical, and social determinants of health data, covering all 50 states.
Key Initiatives:
High-Performance AI Models for Clinical Development:
- Leverages NVIDIA NIMs for scalable, high-performance AI model deployment.
- Enhances clinical trial patient matching, protocol automation, and research site co-pilots.
- Provides real-time analytics and model management for large-scale AI applications.
Large-Scale Multi-Modal Data Processing:
- Utilizes NVIDIA CUDA-X microservices to accelerate data processing pipelines.
- Enhances the management of ConcertAI’s vast oncology data set with faster processing speeds and efficiency.
Development of Precision Oncology and Medical LLMs:
- Foundation models trained on ConcertAI’s multi-modal data support advanced translational simulations.
- Guides first-in-human studies, clinical trial simulations, and clinical decision support.
- Identifies beneficial diagnostic and treatment approaches.
Leadership Insights:
- Jeff Elton, PhD, CEO of ConcertAI: Emphasizes the potential of AI to provide insights in oncology research and treatment that were not possible with prior technologies.
- Kimberly Powell, VP of Healthcare at NVIDIA: Highlights the transformative potential of integrating NVIDIA’s AI tools into ConcertAI’s platform for improving clinical trial design and outcomes.
Conclusion: The collaboration between ConcertAI and NVIDIA represents a significant advancement in oncology research and clinical development. By leveraging NVIDIA’s AI expertise and infrastructure, ConcertAI aims to enhance precision and efficiency in oncology research, ultimately improving patient outcomes. Initial benefits from this collaboration will be available in the CARA AI cloud and solutions by Q3 of 2024, marking a pivotal step towards the future of AI-driven healthcare innovation.